Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

What have we learned from exceptional tumour responses?: Review and perspectives.

Current opinion in oncology - 1 May 2015

Mehra Niven, Lorente David, de Bono Johann S

Abstract excerpt

PURPOSE OF REVIEW: Understanding the basis of exceptional responses may increase our knowledge of disease biology and the mechanism of action of targeted agents, and identify subpopulations of patients who derive important benefit from drugs that would otherwise not be developed due to lack of su...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Genotype

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Precision Medicine

Source

Identifiers

PMID: 25811347
DOI: 10.1097/CCO.0000000000000182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25811347-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

What have we learned from exceptional tumour responses?: Review and perspectives.PMID 25811347Read ↗

Transforming Biomarker Development with Exceptional Responders.Semantic proximity Read ↗

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.Semantic proximity Read ↗

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.Semantic proximity Read ↗

Rare Germline Variants in Immune and Drug Target Genes Among Cancer Exceptional RespondersSemantic proximity Read ↗

Molecular Profiling of Exceptional Responders to Cancer Therapy.Semantic proximity Read ↗

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer.Semantic proximity Read ↗

RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?Semantic proximity Read ↗

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.Semantic proximity Read ↗

Genomic landscape of extraordinary responses in metastatic breast cancer.Semantic proximity Read ↗

Mining the genomes of exceptional responders.Semantic proximity Read ↗

mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?Semantic proximity Read ↗

Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.